-
Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption
Wednesday, July 13, 2016 - 8:55am | 276Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by nearly 25 percent to $34.50 ahead of Wednesday's market open. The biopharma company focused on the treatment of cancer announced after Tuesday's market close that the U.S. Food and Drug Administration removed a clinical hold...
-
These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold
Friday, July 8, 2016 - 11:17am | 347Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...
-
Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug
Thursday, July 7, 2016 - 4:36pm | 355Juno Therapeutics Inc (NASDAQ: JUNO) was halted shortly after Thursday's closing bell. A couple minutes later, the company announced JCAR015's Phase 2 trial was put on hold after two patients died last week. "JCAR015 therapy is being tested among adult patients with acute...